|
|
Article: AstraZeneca: Third Quarter and Nine Months Results 2009.(Financial report)
- Article from:
- Vaccine Weekly
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AstraZeneca (STO:AZN) (LSE:AZN)
Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million (see also AstraZeneca).
-US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.-US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER. -Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.
Core operating profit in the third quarter increased by 29 percent at CER to $3,609 million on revenue growth and ...